Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japan Fabry Research-001 observational study of agalsidase alfa
jRCT1090220293Recruiting
- Sponsor
- Kazuya Tsuboi
- Start
- May 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of agalsidase alfa in Fabry disease (FD) (2 cohorts), sponsored by Kazuya Tsuboi. Primary endpoints: Globotriaosylceramide (Gb3), Globotriaosylsphingosine (Lyso-Gb3) and 5 more. Started May 2017; status: recruiting.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on jRCT1090220293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220293.